Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | CLK1 | P49759 | 2/20 | 0.48 |
| ▸ | CLK2 | P49760 | 2/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | AKT2 | P31751 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733801 | 0.86 | MAP3K5 (0.53) | MAP3K5USP30CLK1CLK2EGLN1 | |
| SCHEMBL2088007 | 0.84 | EGLN1 (0.61) | MAP3K5EGLN1NR4A2CYP2C9ALDH1A1 | |
| SCHEMBL3767210 | 0.82 | CYP2C9 (0.65) | MAP3K5USP30CLK1CLK2EGLN1 | |
| SCHEMBL30845755 | 0.82 | MAP3K5 (0.52) | MAP3K5USP30CLK1CLK2EGLN1 | |
| SCHEMBL1728464 | 0.81 | EGLN1 (0.47) | EGLN1NR4A2CYP2C9ALDH1A1ALDH1A3 | |
| SCHEMBL1728555 | 0.80 | NR4A2 (0.50) | EGLN1NR4A2CYP2C9ALDH1A1ALDH1A3 | |
| SCHEMBL19017615 | 0.79 | MAP3K5 (0.57) | MAP3K5USP30CLK1CLK2EGLN1 | |
| SCHEMBL1730257 | 0.79 | MAP3K5 (0.52) | MAP3K5EGLN1NR4A2CYP2C9ALDH1A1 | |
| SCHEMBL1728471 | 0.79 | NR4A2 (0.70) | EGLN1NR4A2CYP2C9 | |
| SCHEMBL3771071 | 0.78 | KDM4E (0.55) | MAP3K5USP30CLK1CLK2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260033-B1 | 2-benzoylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof | SANOFI SA (FR) | 2011-11-23 | — | — | EP | claimed |
| US-20100317687-A1 | 2-BENZOYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | claimed |
| EP-2260033-B1 | 2-benzoylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof | SANOFI SA (FR) | 2011-11-23 | — | — | EP | disclosed |
| US-20100317687-A1 | 2-BENZOYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317687-A1 | 2-BENZOYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | XDH, REN, GLS | MAP3K5 2856/4885USP30 4725/4885CLK1 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.